Amiodarone induces two different types of disorders in mouse alveolar macrophages

Japanese Journal of Pharmacology

Volumn 74, Issue 1, 1997, Pages 21-28

  Futamura, Yoshihiro ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Alveolar macrophage; Amiodarone; Cationic amphiphilic drug; H+ ATPase; Pulmonary toxicity

Indexed keywords

AMANTADINE; AMIODARONE; AMPHOPHILE; CATION; CYTOKINE; INTERLEUKIN 1BETA; MIANSERIN; NEUTRAL RED; PHOSPHOLIPASE A2; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTEIN KINASE C; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE;

ANIMAL CELL; ARTICLE; CELL PH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; LUNG ALVEOLUS MACROPHAGE; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROSTAGLANDIN RELEASE;

EID: 0030918408     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.74.21     Document Type: Article

References (30)

1. Gill J, Heel RC and Fitton A: Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43, 69-110 (1992)
2. Suárez LD, Poderoso JJ, Elsner B, Bunster AM, Esteva H and Bellotti M: Subacute pneumopathy during amiodarone therapy. Chest 3, 566-568 (1983)
3. Sobol SM and Rakita L: Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new antiarryhythmic drug. Circulation 65, 819-824 (1982)
4. Marchlinski FE, Gansler TS, Waxman HL and Josephson ME: Amiodarone pulmonary toxicity. Ann Intern Med 97, 839-845 (1982)
5. Martin WJ II and Standing JE: Amiodarone pulmonary toxicity: Biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. J Pharmacol Exp Ther 244, 774-779 (1988)
6. Lüllmann H, Lüllmann-Rauch R and Wassermann O: Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol 27, 1103-1108 (1978)
7. Hruban Z: Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ Health Perspect 55, 53-76 (1984)
8. Hosteller KY and Matsuzawa Y: Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C. Biochem Pharmacol 20, 1121-1126 (1981)
9. Futamura Y: Effect of amiodarone on release of cytokines from mouse alveolar macrophages pretreated with eicosapentaenoic acid. Jpn J Pharmacol 69, 335-341 (1995)
10. Jaffrézou JP, Chen G, Durán GE, Muller C, Bordier C, Laurent G, Sikic BI and Levade T: Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim Biophys Acta 1266, 1-8 (1995)
11. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M and Satoyoshi E: Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem 98, 1669-1679 (1985)
12. Otterbach B and Stoffel W: Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick Disease). Cell 81, 1053-1061 (1995)
13. Pappu A and Hostetler KY: Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochem Pharmacol 33, 1639-1644 (1984)
14. Martin WJ II, Kachel DL, Vilen T and Natarajan V: Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J Pharmacol Exp Ther 251, 272-278 (1989)
15. Nguyen BT, Peterson PK, Verbrugh HA, Quie PG and Hoidal JR: Differences in phagocytosis and killing by alveolar macrophages from humans, rabbits, rats and hamsters. Infect Immun 36, 504-509 (1982)
16. Ohno T, Itagaki H, Tanaka N and Ono H: Validation study on five different cytotoxicity assays in Japan - an intermediate report. Toxic In Vitro 9, 571-576 (1995)
17. Kelley J, Fabisiak, JP, Hawes K and Abscher M: Cytokine signaling in lung: transforming growth factor β secretion by lung fibroblasts. Am J Physiol 260, L123-L128 (1991)
18. Hannun YA, Loomis CR, Merrill AH and Bell RM: Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem 261, 12604-12609 (1986)
19. Riva E, Gerna M, Neyroz P, Urso R, Bartosek I and Guaitani A: Pharmacokinetics of amiodarone in rats. J Cardiovasc Pharmacol 4, 270-275 (1982)
20. Futamura Y and Matsumoto K: Age-associated changes of cytokine levels in bone marrow of Wistar rat. Exp Anim 42, 643-645 (1993) (Abstr in English)
21. + pump in membrane vesicles from rat kidney cortex. Am J Physiol 248, F835-F844 (1985)
22. 2 with pyrene-labeled lecithin as a substrate. Anal Biochem 116, 553-558 (1981)
23. Coles L and Gray GM: Fluorimetric determination of sphingosine and its application to natural mixtures of glycosphingolipids. J Lipid Res 11, 164-166 (1970)
24. Horn S, Bashan N and Gopas J: Phagocytosis of phenylhydrazine oxidized and G-6-PD-deficient red blood cells: The role of cell-bound immunoglobulins. Blood 78, 1818-1825 (1991)
25. Anderson RE, Woodbury DM and Jee WSS: Humoral and ionic regulation of osteoclast acidity. Calcif Tissue Int 39, 252-258 (1986)
26. Akoun GM, Gauthier-Rahman S, Milleron BJ, Perot JY and Mayaud CM: Amiodarone-induced hypersensitivity pneumonias. Evidence of an immunological cell-mediated mechanism. Chest 85, 133-135 (1984)
27. Karpel JP, Mitsudo S and Norin AJ: Natural killer cell activity in a rat model of amiodarone-induced interstitial lung disease. Chest 99, 230-234 (1991)
28. Akoun GM, Milleron BJ, Badaro DM, Mayaud CM and Liote HA: Pleural T-lymphocyte subsets in amiodarone-associated pleuropneumonitis. Chest 95, 596-597 (1989)
29. Kannan R, Sarma JSM, Guha M and Venkataraman K: Amiodarone toxicity. II. Desethylamiodarone-induced phospholipidosis and ultrastructural changes during repeated administration in rats. Fundam Appl Toxicol 16, 103-109 (1991)
30. Rotmensch HH and Belhassen B: Amiodarone in the management of cardiac arrhythmias: current concepts. Med Clin North Am 72, 321-357 (1988)